194985-94-9

Basic information

• Product Name: 3-HYDROXY-4-BENZYLOXYBENZONITRILE
• Synonyms: 3-HYDROXY-4-BENZYLOXYBENZONITRILE;4-BENZYLOXY-3-HYDROXYBENZONITRILE;2-(Benzyloxy)-5-cyanophenol
• CAS NO: 194985-94-9
• Molecular Formula: C₁₄H₁₁NO₂
• Molecular Weight: 0
• Mol File: 194985-94-9.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-HYDROXY-4-BENZYLOXYBENZONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-HYDROXY-4-BENZYLOXYBENZONITRILE(194985-94-9)
• EPA Substance Registry System: 3-HYDROXY-4-BENZYLOXYBENZONITRILE(194985-94-9)

Safety Data

• Hazardous Substances Data: 194985-94-9(Hazardous Substances Data)

Upstream product

• 17345-61-8 3,4-dihydroxybenzonitrile 
• 100-39-0 benzyl bromide 
• 4049-39-2 4-benzyloxy-3-hydroxy-benzaldehyde 

Downstream Products

• 203926-02-7 2-(2-benzyloxy-5-cyanophenoxy)-4-benzylamino-5-nitro-6-(3-dimethylaminocarbonylphenoxy)pyrimidine 
• 200011-89-8 2-(2-Benzyloxy-5-cyanophenoxy)-4-(ethoxycarbonylmethyl)amino-5-nitro-6-(3-(dimethylaminocarbonyl)phenoxy)pyrimidine 
• 203925-87-5 2-methylthio-4-chloro-5-nitro-6-(2-benzyloxy-5-cyanophenoxy)pyrimidine 
• 426826-63-3 4-[2-[5-cyano-2-(phenylmethoxy)phenoxy]-3,5,6-trifluoropyridin-4-yl]oxy-3-methoxybenzoic acid, ethyl ester 
• 439801-32-8 2-chloro-6-(5-cyano-2-benzyloxyphenoxy)pyridine-4-carboxylic acid ethyl ester 
• 518058-76-9 4-benzyloxy-3-hydroxybenzylamine 
• 205176-41-6 3,5-di(benzyloxy)benzylamine 
• 252263-63-1 benzyl (3R)-3-t-butoxycarbonylamino-4-(5-cyano-2-benzyloxyphenoxy)butanoate 
• 858673-95-7 4-Benzyloxy-3-(4-benzyloxybutoxy)benzonitrile 
• 1017022-14-8 C₁₅H₁₆N₂O₃ 
• 1163715-93-2 3-(4-(benzyloxy)-3-methoxyphenyl)-5-(pyridin-4-yl)-1,2,4-oxadiazole 
• 52805-34-2 4-(benzyloxy)-3-methoxybenzonitrile 
• 439801-33-9 2-(5-cyano-2-benzyloxyphenoxy)-6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridine-4-carboxylic acid ethyl ester 

Relevant articles and documents

Design and Synthesis of 3,5-Disubstituted-1,2,4-Oxadiazoles as Potent Inhibitors of Phosphodiesterase4B2

A series of 3,5-disubstituted-1,2,4-oxadiazoles has been prepared and evaluated for phosphodiesterase inhibition (PDE4B2). Among the prepared 3,5-disubstituted-1,2,4-oxadiazoles, compound 9a is the most potent inhibitor (PDE4B2 IC50=5.28μm). Structure-activity relationship studies of 3,5-disubstituted-1,2,4-oxadiazoles revealed that substituents 3-cyclopentyloxy-4-methoxyphenyl group at 3-position and cyclic ring bearing heteroatoms at 5-position are important for activity. Molecular modeling study of the 3,5-disubstituted-1,2,4-oxadiazoles with PDE4B has shown similar interactions of 3-cyclopentyloxy-4-methoxyphenyl group; however, heteroatom ring is slightly deviating when compared to Piclamilast. 3-(3-Cyclopentyloxy-4-methoxyphenyl)-5-(piperidin-4-yl)-1,2,4-oxadiazole (9a) exhibited good analgesic and antiinflammatory activities in formalin-induced pain in mice and carrageenan-induced paw edema model in rat.

Bicyclic compositions and methods for modulating a kinase cascade

The invention relates to compounds and methods for modulating one or more components of a kinase cascade.

Purinenucleoside derivative modified in 8-position and medical use thereof

The present invention provides an 8-modified purinenucleoside derivative which is useful for diseases associated with an abnormality of plasma uric acid level. An 8-modified purinenucleoside derivative represented by the following formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, is useful for the prevention or treatment of gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy or the like. In the formula, n is 1 or 2; RA is a hydrogen atom or a hydroxyl group; R1 is a hydrogen atom, a hydroxyl group, a thiol group, an amino group or a chlorine atom; ring J represents an optionally substituted 2-naphthyl group, or a group represented by the following general formula (II) wherein Y represents a single bond or a connecting group; ring Z represents an optionally substituted aryl group or heteroaryl group or the like; and R2 to R4, P1 and Q represents a halogen atom, a cyano group or the like.

NOVEL BENZAMIDINE COMPOUND

The present invention relates to a novel compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof. wherein each symbol is as defined in the specification. According to the present invention, an activated blood coagul

BENZIMIDAZOLE DERIVATIVES AND MEDICAL USES THEREOF

The present invention providesbenzimidazole derivatives represented by the following formula (I) or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exert an inhibitory activity on sodium-dependent nucleoside transporter 2 and are useful for a disease associated with an abnormality of plasma uric acid level. The compounds of the present invention are useful for the prevention or treatment of gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy or the like. In the formula, n is 1 or 2; R1 and R2 are H, a halogen atom, cyano group, optionally substituted alkyl group, optionally substituted aryl group or the like; R3 is H, a halogen atom, optionally substituted alkyl group or the like; R9 and R5 are H, a halogen atom, OH or the like; and R6 and RX are H or OH: RY is F or OH.

NOVEL BENZAMIDINE COMPOUND

A novel compound, or a pharmaceutically acceptable salt thereof, represented by the formula (1) wherein the characters are as defined in the description. Thus, there can be provided an activated blood coagulation factor X inhibitor and a novel anti(blood)

Protein kinase and phosphatase inhibitors and methods for designing them

The present invention provides a method for identifying inhibitors of protein kinases and/or protein phosphatases. Methods are also provided for inhibiting protein kinase and/or protein phosphatase activity. Specific non-peptide protein tyrosine kinase and/or protein phosphatase inhibitors are provided. The protein kinase or protein phosphatase inhibitors of the present invention may be used to treat a number of conditions in patients, including cancer, psoriasis, arthrosclerosis, immune system activity, Type II diabetes, and obesity.

Benzamidine derivatives

Benzamidine derivatives of the following formula, analogs thereof and pharmaceutically acceptable salts thereof are provided. These compounds have an effect of inhibiting activated blood-coagulation factor X, and they are useful as agents for preventing or treating various diseases caused by thrombi or emboli.